Status:

RECRUITING

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Lead Sponsor:

Mayo Clinic

Conditions:

Breast Adenocarcinoma

HER2-Positive Breast Carcinoma

Eligibility:

FEMALE

18+ years

Brief Summary

This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2 positive...

Detailed Description

PRIMARY OBJECTIVES I. To determine the correlation between HER2 specific T-cell response in HER2-positive breast cancer patients with stage I-IV who receive anti-HER2 therapies, such as trastuzumab, p...

Eligibility Criteria

Inclusion

  • Age \>= 18 years
  • Histological confirmed adenocarcinoma of the breast stage I-IV from the American Joint Committee on Cancer staging 8th edition
  • Any estrogen receptor (ER) or progesterone receptor (PR) but HER2 positive defined as per the most current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline
  • Provide written informed consent
  • Willingness to provide blood samples for correlative research purposes
  • BLOOD AND TISSUE COHORT: Scheduled to start new anti-HER2 therapy/therapies
  • TISSUE-ONLY COHORT: Received or previously completed anti-HER2 therapy/therapies

Exclusion

  • Immunocompromised patients including patients known to be human immunodeficiency virus (HIV) positive
  • Receiving systemic steroid therapy or any other immunosuppressive therapy =\< 30 days prior to registration. NOTE: Inhaled steroids, low-dose corticosteroids (e.g. equivalent to or less than oral prednisone 10 mg daily), and steroid use for primary prevention of nausea per institutional guidelines are allowed.

Key Trial Info

Start Date :

July 31 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 27 2028

Estimated Enrollment :

230 Patients enrolled

Trial Details

Trial ID

NCT04517838

Start Date

July 31 2020

End Date

July 27 2028

Last Update

December 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mayo Clinic in Florida

Jacksonville, Florida, United States, 32224-9980

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer | DecenTrialz